Affiliation:
1. Semmelweis Egyetem, Gyógyszerésztudományi Kar Gyógyszerhatástani Intézet Budapest Nagyvárad tér 4. 1089
2. Semmelweis Egyetem, Általános Orvostudományi Kar Kútvölgyi Klinikai Tömb, Klinikai és Kutatási Mentálhigiénés Osztály Budapest
3. Magyar Tudományos Akadémia–Semmelweis Egyetem Neuropszichofarmakológiai és Neurokémiai Kutatócsoport Budapest
Abstract
Although medications such as anticancer, antimicrobial, immunomodulatory, neurological or hormonal therapies may have a negative impact on mood, adequate attention was not paid until the withdrawal of rimonabant in 2008. In the present study the authors review full spectrum of currently available medications discussing anxiety and depression as possible adverse effects of treatment. A relatively high risk of depression should always be considered when pharmacotherapy applied, especially if current depressive episodes, positive family history, or neurotic personality traits increasing susceptibility to depressogenic effects. Prior to start of medical treatment, the potential effectiveness of the given drug should be precisely evaluated, and alternative medical and non-medical treatment options should also be carefully considered. In addition, monitoring patients during treatment for signs of depressive or anxious symptoms is necessary. Orv. Hetil., 2013, 154, 1327–1336.